miR-205 Targets PTEN and PHLPP2 to Augment AKT Signaling and Drive Malignant Phenotypes in Non-Small Cell Lung Cancer

被引:182
作者
Cai, Junchao [1 ,3 ]
Fang, Lishan [1 ,3 ]
Huang, Yongbo [1 ,3 ]
Li, Rong [1 ,3 ]
Yuan, Jie [4 ]
Yang, Yi [2 ,3 ]
Zhu, Xun [1 ,3 ]
Chen, Baixue [1 ,3 ]
Wu, Jueheng [1 ,3 ]
Li, Mengfeng [1 ,3 ]
机构
[1] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou 510080, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou 510080, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou 510080, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Dept Educ Guangdong Prov, Key Lab Funct Mol Ocean Microorganisms, Guangzhou 510080, Guangdong, Peoples R China
关键词
NF-KAPPA-B; EXPRESSION; SURVIVAL; KINASE; MTOR; OVEREXPRESSION; ACTIVATION; RESISTANCE; INHIBITORS; MICRORNAS;
D O I
10.1158/0008-5472.CAN-13-0297
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
AKT signaling is constitutively activated in various cancers, due in large part to loss-of-function in the PTEN and PHLPP phosphatases that act as tumor suppressor genes. However, AKT signaling is activated widely in non-small cell lung cancers (NSCLC) where genetic alterations in PTEN or PHLPP genes are rare, suggesting an undefined mechanism(s) for their suppression. In this study, we report upregulation of the oncomir microRNA (miR)-205 in multiple subtypes of NSCLC, which directly represses PTEN and PHLPP2 expression and activates both the AKT/FOXO3a and AKT/mTOR signaling pathways. miR-205 overexpression in NSCLC cells accelerated tumor cell proliferation and promoted blood vessel formation in vitro and in vivo. Conversely, RNA interference-mediated silencing of endogenous miR-205 abrogated these effects. The malignant properties induced by miR-205 in NSCLC cells were reversed by AKT inhibitors, FOXO3a overexpression, rapamycin treatment, or restoring PHLPP2 or PTEN expression. Mechanistic investigations revealed that miR-205 overexpression was a result of NF-kappa B-mediated transactivation of the miR-205 gene. Taken together, our results define a major epigenetic mechanism for suppression of PTEN and PHLPP2 in NSCLC, identifying a pivotal role for miR-205 in development and progression of this widespread disease. Cancer Res; 73(17); 5402-15. (C) 2013 AACR.
引用
收藏
页码:5402 / 5415
页数:14
相关论文
共 46 条
[1]   The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention [J].
Alao, John P. .
MOLECULAR CANCER, 2007, 6 (1)
[2]   Perturbations of the AKT signaling pathway in human cancer [J].
Altomare, DA ;
Testa, JR .
ONCOGENE, 2005, 24 (50) :7455-7464
[3]   Activation of AKT kinases in cancer: Implications for therapeutic targeting [J].
Bellacosa, A ;
Kumar, CC ;
Di Cristofano, A ;
Testa, JR .
ADVANCES IN CANCER RESEARCH, VOL 94, 2005, 94 :29-+
[4]   RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer [J].
Bepler, G ;
Sharma, S ;
Cantor, A ;
Gautam, A ;
Haura, E ;
Simon, G ;
Sharma, A ;
Sommers, E ;
Robinson, L .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1878-1885
[5]   FOXO3a elicits a pro-apoptotic transcription program and cellular response to human lung carcinogen nicotine-derived nitrosaminoketone (NNK) [J].
Blake, Daniel C., Jr. ;
Mikse, Oliver R. ;
Freeman, Willard M. ;
Herzog, Christopher R. .
LUNG CANCER, 2010, 67 (01) :37-47
[6]  
Brognard J, 2001, CANCER RES, V61, P3986
[7]   PHUPPing the switch on Akt and protein kinase C signaling [J].
Brognard, John ;
Newton, Alexandra C. .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2008, 19 (06) :223-230
[8]   PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms [J].
Brognard, John ;
Sierecki, Emma ;
Gao, Tianyan ;
Newton, Alexandra C. .
MOLECULAR CELL, 2007, 25 (06) :917-931
[9]  
Buyukcelik Abdullah, 2004, N Engl J Med, V350, P2008
[10]   miR-186 Downregulation Correlates with Poor Survival in Lung Adenocarcinoma, Where It Interferes with Cell-Cycle Regulation [J].
Cai, Junchao ;
Wu, Jueheng ;
Zhang, Huizhong ;
Fang, Lishan ;
Huang, Yongbo ;
Yang, Yi ;
Zhu, Xun ;
Li, Rong ;
Li, Mengfeng .
CANCER RESEARCH, 2013, 73 (02) :756-766